此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

吉西他滨/顺铂加 Cemiplimab(REGN2810,抗 PD-1)联合或不联合 Fianlimab(REGN3767,抗 LAG-3)治疗局限性肌层浸润性膀胱癌 (NeoSTOP-IT) 患者的研究 (NeoSTOP-IT)

2026年10月12日 更新者:Alexander Z. Wei, MD、Columbia University

吉西他滨/顺铂加 Cemiplimab(REGN2810,抗 PD-1)联合或不联合 Fianlimab(REGN3767,抗 LAG-3)用于局部肌层浸润性膀胱癌患者器官保存的 2 期随机、开放标签研究(NeoSTOP-IT)

The goal of this clinical trial is to learn if gemcitabine/cisplatin plus cemiplimab with or without fianlimab works to treat bladder cancer in adults. The main question it aims to answer is: Can gemcitabine, cisplatin, and cemiplimab with or without fianlimab treat bladder cancer?

Participants will be randomly selected (like the loss of a coin) to treatment with gemcitabine, cisplatin, cemiplimab, and fianlimab or gemcitabine, cisplatin, and cemiplimab.

Participants will:

  • Undergo transurethral resection of bladder tumor (TURBT) followed by the start of treatment, receive 4 cycles of treatment (21 day cycles)
  • After 4 cycles of treatment, patients will undergo repeat maximal TURBT with imaging
  • Participants with a complete response will continue maintenance cemiplimab or cemiplimab/fianlimab for 13 more cycles with imaging every 3 months
  • Participants without a complete clinical response will undergo cystectomy (bladder surgery).

研究概览

详细说明

This is a phase 2, open-label, randomized trial with continuous toxicity monitoring to ensure safety using Bayesian toxicity monitoring, which will evaluate treatment with doublet platinum-based chemotherapy (gemcitabine and cisplatin) plus cemiplimab (REGN2810) with or without fianlimab (REGN3767) for localized muscle-invasive bladder cancer (MIBC). Participants will be randomized to 4 cycles of 3 weeks each (12 weeks total) with gemcitabine, cisplatin, and cemiplimab with or without fianlimab. Participants achieving a clinical complete response will continue 13 more cycles of immunotherapy (39 weeks total). The total duration of systemic treatment, including neoadjuvant therapy, will be 52 weeks.

In addition to the actual time on treatment, there will be time off treatment for recovery after neoadjuvant treatment and before adjuvant treatment. First, between the neoadjuvant phase and cystoscopy (with TURBT for residual disease), there will be up to 4 weeks off treatment. In between the cystoscopy/TURBT and start of adjuvant immunotherapy, there will be an additional up to 4 week interval for recovery. Participants will have regularly scheduled study visits at the clinical site on Day 1 and Day 8 of every three-week cycle in the neoadjuvant setting, where continuous assessment, including treatment response and safety assessments, will be performed. These will include laboratory tests, taking of vital signs, and physical examinations. In the adjuvant setting for participants who continue to maintenance immunotherapy, participants will have regularly scheduled study visits at the clinical site on Day 1 of every three-week cycle.

Response to treatment will be determined by three modalities. First, CT scans (chest, abdomen, and pelvis with and without contrast) to ensure no metastatic disease. For participants who are unable to get a CT scan w/ contrast due to renal function (or any other reason), an MRI with and without contrast may be used instead. Scans are required at baseline and every 3 months in the adjuvant setting for participants who continue on with maintenance immunotherapy. Second, all participants will undergo post-treatment cystoscopy every 3 months while on treatment. Third, all participants will undergo post-treatment urine cytology every 3 months while on treatment.

研究类型

介入性

注册 (实际的)

1

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • New York
      • New York、New York、美国、10032
        • Columbia University Irving Medical Center/ New York Presbyterian Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Willing and able to provide written informed consent for the trial.
  • Age ≥18 years of age on day of signing informed consent.
  • Life expectancy > 12 months.
  • Performance status of 0-1 using the Eastern Cooperative Oncology Group (ECOG) Performance Scale.
  • Histologically confirmed muscle-invasive urothelial carcinoma of the bladder defined as T2-T3, N0, M0 stage. Mixed histology is permitted if there is a urothelial component. Upper tract disease in not permitted.
  • Prior Bacillus Calmette-Guerin (BCG) or other intravesical treatment of non-muscle invasive bladder cancer is permitted if completed at least 6 weeks prior to initiating study treatment. Only one course (includes induction + maintenance) of BCG or intravesical therapy is permitted.
  • No metastatic disease based on cross-sectional imaging.
  • Considered cisplatin eligible based on protocol specified criteria.
  • Not received any adjuvant or neoadjuvant chemotherapy or immunotherapy.
  • Agree to pre- and post-treatment TURBT as well as surveillance with cystoscopies, cross-sectional imaging, and urine cytology unless medically contraindicated in the opinion of the treating physician, and discussed with the principal investigator

Exclusion Criteria:

  • Concurrent upper urinary tract (i.e., ureter, renal pelvis) invasive urothelial carcinoma. (NOTE: Patients with history of non-invasive (Ta, Tis) upper tract urothelial carcinoma that has been definitively treated with at least one post- treatment disease assessment (i.e. cytology, biopsy, imaging) that demonstrates no evidence of residual disease are eligible).
  • Received prior immune checkpoint inhibitors (including anti-PD-1, anti-PD-L1, anti-CTLA4, anti-LAG-3 or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways ), as well as cellular vaccines, cellular therapies, or systemic oncolytic virus therapy.
  • Received bladder-directed radiation therapy previously for bladder cancer.
  • Received prior systemic chemotherapy for muscle-invasive bladder cancer.
  • Receiving any other investigational agents concurrently or within 4 weeks of start of treatment.
  • Had a solid organ or hematologic transplant.
  • Ongoing or recent (within 2 years) evidence of an autoimmune disease that required systemic treatment with immunosuppressive agents. The following are non-exclusionary: vitiligo, childhood asthma that has resolved, residual hypothyroidism that requires only hormone replacement, psoriasis not requiring systemic treatment
  • Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (at a dose greater than 10mg/day of prednisone equivalent) or any other form of immunosuppressive therapy within 14 days prior to the first dose of trial treatment. Inhaled or topical steroids, and adrenal replacement steroid doses >10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
  • Has a history of myocarditis.
  • Patients with another active second malignancy other than non-melanoma skin cancers.
  • Has a known history of, or any evidence of, interstitial lung disease or active noninfectious pneumonitis.
  • Has an active infection requiring systemic therapy.
  • History or current evidence of significant (Common Terminology Criteria for Adverse Events (CTCAE) grade ≥2) local or systemic infection (eg, cellulitis, pneumonia, septicemia) requiring systemic antibiotic treatment within 2 weeks prior to the first dose of trial medication.
  • Has a history of current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator, including dialysis.
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  • Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection; or diagnosis of immunodeficiency that is related to, or results in chronic infection.
  • Is pregnant or is a breastfeeding woman.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Group 1: Gemcitabine/Cisplatin/Cemiplimab
  • Gemcitabine 1000 mg/m^2 IV (days 1 and 8 of 21 day for 4 cycles)
  • Cisplatin 70 mg/m^2 IV (day 1 of 21 day cycle for 4 cycles) or renally-dosed split-dose -cisplatin 35 m/m^2 IV (day 1 and 8 of 21 day cycle for 4 cycles)
  • Cemiplimab (REGN 2810) 350 mg IV every 3 weeks (17 cycles)

Gemcitabine 1000 mg/m^2 IV

Cisplatin 70 mg/m^2 IV or renally-dosed split-dose cisplatin 35 m/m^2 IV

Cemiplimab 350mg IV

其他名称:
  • 雷根2810
实验性的:Group 2: Gemcitabine/Cisplatin/Cemiplimab/Fianlimab
  • Gemcitabine 1000 mg/m2 IV (days 1 and 8 of 21 day cycle for 4 cycles)
  • Cisplatin 70 mg/m2 IV (day 1 of 21 day cycle for 4 cycles) or renally-dosed split-dose cisplatin 35 m/m2 IV (day 1 and 8 of 21 day cycle for 4 cycles )
  • Cemiplimab (REGN 2810) 350mg IV every 3 weeks (4 cycles)
  • Fianlimab (REGN3767) 1600mg IV every 3 weeks (4 cycles)

Gemcitabine 1000 mg/m^2 IV

Cisplatin 70 mg/m^2 IV or renally-dosed split-dose cisplatin 35 m/m^2 IV

Cemiplimab 350mg IV

其他名称:
  • 雷根2810

Fianlimab 1600mg IV

其他名称:
  • REGN3767

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Clinical Complete Response
大体时间:16 weeks

Rate of clinical complete response after 4 cycles of neoadjuvant chemoimmunotherapy. Complete clinical response will be defined as:

  • No high-grade malignancy on repeat TURBT
  • No malignant cells on urine cytology
  • No definitive evidence of invasive local or metastatic disease on cross-sectional imaging (CT chest, abdomen, and pelvis with contrast or, if renal dysfunction, MRI with contrast)

Cytoscopy and imaging should occur within 4 weeks of end of neoadjuvant therapy.

16 weeks

次要结果测量

结果测量
措施说明
大体时间
Number of Adverse Events
大体时间:30 days after last dose of treatment, up to 56 weeks

Defined as the occurrence of any adverse event (AE) related to the investigational drugs at any point on treatment until 30 days after the last dose of treatment. AEs as evaluated per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

30 days after last dose of treatment, up to 56 weeks
Bladder-intact Survival
大体时间:Up to 5 years

Bladder-intact survival is defined as the time from start of treatment until cystectomy or death.

Up to 5 years
Recurrence-free Survival
大体时间:Up to 5 years

Recurrence-free survival is defined as the time from start of treatment until disease recurrence or death. Recurrence-survival will only be measured in patients who achieve a clinical complete response.

Up to 5 years
Overall Survival
大体时间:Up to 5 years

Overall survival is defined as the time from start of treatment until death.

Up to 5 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Alexander Z Wei, MD、Columbia University

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年8月14日

初级完成 (实际的)

2026年1月5日

研究完成 (实际的)

2026年1月5日

研究注册日期

首次提交

2024年8月23日

首先提交符合 QC 标准的

2024年8月23日

首次发布 (实际的)

2024年8月26日

研究记录更新

最后更新发布 (实际的)

2026年11月3日

上次提交的符合 QC 标准的更新

2026年10月12日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅